Equity Overview
Price & Market Data
Price: $9.29
Daily Change: -$0.50 / 5.38%
Range: $9.02 - $9.87
Market Cap: $800,513,152
Volume: 1,257,822
Performance Metrics
1 Week: 0.77%
1 Month: 15.43%
3 Months: 4.90%
6 Months: -33.81%
1 Year: -41.40%
YTD: -13.37%
Company Details
Employees: 118
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. Its preclinical assets include IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, including IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.